Terminated COVID-19 Trial Leaves Maraviroc and Favipiravir Questions Unanswered
A Phase 2 trial testing maraviroc and favipiravir for severe COVID-19 was terminated before completion, leaving efficacy data incomplete.
Summary
This Phase 2 randomized trial from Hospital General de México tested whether adding maraviroc, favipiravir, or both to standard care could improve outcomes in hospitalized adults with severe COVID-19 pneumonia. The study enrolled patients into three active treatment arms alongside a standard-of-care control group. However, the trial was terminated before reaching completion, meaning definitive conclusions about the safety and efficacy of either drug cannot be drawn from this study alone. Maraviroc is an antiretroviral CCR5 antagonist originally approved for HIV, while favipiravir is a broad-spectrum antiviral that inhibits viral RNA polymerase. Both had been proposed as candidates for COVID-19 repurposing based on their mechanisms. The termination highlights the challenges of conducting rigorous antiviral trials during a rapidly evolving pandemic.
Detailed Summary
The COVID-19 pandemic prompted urgent efforts to repurpose existing antivirals against SARS-CoV-2. Two drugs attracted particular interest: maraviroc, a CCR5 antagonist approved for HIV, and favipiravir, a broad-spectrum viral RNA polymerase inhibitor used against influenza in some countries. Both had plausible mechanistic rationales for COVID-19 benefit, prompting clinical investigation.
This Phase 2, randomized, open-label study was conducted at Hospital General de México Dr. Eduardo Liceaga. The trial enrolled hospitalized adults with pulmonary SARS-CoV-2 infection and tested maraviroc added to standard therapy, favipiravir added to standard therapy, the combination of both drugs with standard therapy, and standard therapy alone. The primary goal was to evaluate safety and efficacy across these arms in a severe, non-ICU COVID-19 population.
Unfortunately, the trial was terminated before completion. No results data are publicly available beyond the trial registration, making it impossible to assess whether either drug demonstrated clinical benefit, harm, or neutral effect in this population. Reasons for termination were not specified in the registration record and may include enrollment challenges, interim futility, safety signals, or resource constraints — all common causes of pandemic-era trial discontinuation.
From a broader perspective, this trial reflects the enormous difficulty of conducting controlled antiviral research during a public health emergency. Many COVID-19 trials were launched rapidly and subsequently terminated, contributing to a fragmented evidence base. Maraviroc has since attracted renewed interest as a potential modulator of inflammation and immune aging, including in longevity research contexts, making its COVID-19 trial history relevant background.
Clinicians and researchers should interpret this termination as an evidence gap rather than a negative result. Until completed trials or robust meta-analyses address these agents in severe COVID-19, no firm conclusions about maraviroc or favipiravir efficacy in this context should be drawn.
Key Findings
- Trial was terminated before completion; no efficacy or safety results are publicly available.
- Maraviroc (CCR5 antagonist) and favipiravir (RNA polymerase inhibitor) were tested as COVID-19 add-on therapies.
- Three active drug arms were compared against standard-of-care in severe non-critical COVID-19 adults.
- Termination highlights persistent challenges in completing antiviral trials during pandemic conditions.
- Maraviroc's CCR5 mechanism continues to attract interest beyond COVID-19, including in aging and inflammation research.
Methodology
Phase 2, randomized, open-label design with four arms: maraviroc plus standard care, favipiravir plus standard care, combination of both plus standard care, and standard care alone. Conducted at a single Mexican academic medical center in hospitalized severe COVID-19 adults. The trial was terminated prior to completion; no outcome data have been published.
Study Limitations
The summary is based on the abstract and trial registration record only, as full results were never published due to termination. Reasons for trial termination, enrollment numbers, and any interim safety or efficacy data are unknown. This represents a significant evidence gap rather than a definitive finding in either direction.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.